Australia markets closed

Algernon Pharmaceuticals Inc. (AGNPF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.07000.0000 (0.00%)
At close: 3:22PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.0700
Open0.0700
BidN/A x N/A
AskN/A x N/A
Day's range0.0672 - 0.0720
52-week range0.0600 - 0.4385
Volume89,891
Avg. volume355,280
Market cap11.253M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-0.0580
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Algernon Pharmaceuticals Announces 70% Enrollment of its Ifenprodil IPF and Chronic Cough Phase 2 Human Study
    GlobeNewswire

    Algernon Pharmaceuticals Announces 70% Enrollment of its Ifenprodil IPF and Chronic Cough Phase 2 Human Study

    VANCOUVER, British Columbia, July 07, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development company, announces that it has reached 70% of its enrollment target for its Phase 2 clinical study of its re-purposed drug NP-120 (Ifenprodil) for idiopathic pulmonary fibrosis (IPF) and chronic cough. The purpose of this 20-patient proof-of-concept Phase 2 human trial is to determine the

  • Algernon Pharmaceuticals Announces it Will Not Advance Ifenprodil into Phase 3 Trial for COVID-19
    GlobeNewswire

    Algernon Pharmaceuticals Announces it Will Not Advance Ifenprodil into Phase 3 Trial for COVID-19

    VANCOUVER, British Columbia, July 06, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, announces that it will not be advancing Ifenprodil into a Phase 3 clinical study for COVID-19. The Company’s decision was based on several factors including the overall findings of the Phase 2b COVID-19 study final data set, the global rate of vaccinations to date, other COVID-19

  • Algernon Pharmaceuticals Targets First Human Study of its Psychedelic Drug DMT Stroke Program for Q4, 2021
    GlobeNewswire

    Algernon Pharmaceuticals Targets First Human Study of its Psychedelic Drug DMT Stroke Program for Q4, 2021

    VANCOUVER, British Columbia, June 17, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) is pleased to announce that all of the required permits and licenses for the manufacture of its cGMP supply of AP-188 (“N, N-Dimethyltryptamine or DMT”) have been received and as a result, is targeting its Phase 1 human study to be conducted at Hammersmith Medicines Research UK in Q4, 2021. The Company awarded the contract to manufa